Santa Clara, CA – July 29, 2025 – Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and cloud platform, is proud to announce the latest recipients of its 2024–2025 Clinical Trial Sponsorship Program.
The program supports the use of EEG in real-world healthcare and clinical research applications by providing teams with access to Zeto’s innovative, rapid-setup, gel-free EEG solution.
“The selected projects reflect the diverse and expanding role of EEG in improving patient outcomes across settings,” said Zoltan Nadasdy, Ph.D., Principal Neuroscientist at Zeto. “From concussion studies in athletes to seizure detection in low-resource ICUs, these projects reflect the power of EEG to transform patient care globally – and the flexibility of Zeto to make it possible.”
The winners are:
Pilot Evaluation of Continuous EEG Implementation for Seizure and Status Epilepticus Management in Zambia (PRECISE-Z) by Clio Rubinos, MD, University of North Carolina
This trial aims to implement continuous EEG (cEEG) monitoring for critically ill patients with altered mental status in Zambia, evaluating its feasibility and acceptability in a resource-limited setting. It also seeks to develop a clinical prediction score to identify patients at highest risk for electrographic seizures and status epilepticus. As one of the first studies exploring cEEG in a lower- to middle-income inpatient setting, it will lay crucial groundwork for improving neurocritical care and reducing disparities in global neurological outcomes.
Optimizing emergency stroke transport strategies using EEG-based biomarkers and machine learning by F. Samuel Racz, MD, University of Texas at Austin
This project aims to improve emergency stroke care by developing a machine learning-based tool that uses EEG recordings to distinguish large vessel occlusion strokes from other conditions with similar early symptoms – before the patient arrives at the hospital. By enabling real-time assessment in the ambulance, this system could help guide whether a patient needs to be transported to the nearest emergency room or instead an endovascular thrombectomy-capable center. If validated, the approach could support future efforts to streamline and optimize stroke triage protocols and reduce treatment delays.
Contribution of Resting and Dynamic Electroencephalogram (EEG) to Assess Athletes Before and After Acute Concussion by Maria Martinez, Ph.D,, University of São Paulo, Brazil
This research will use EEG to evaluate brain activity changes in athletes before and after acute concussion, supporting improved assessment and return-to-play decisions.
Each project will receive Zeto ONE EEG headsets, access to Zeto’s cloud platform, and electrode kits for participants. Trials are expected to begin later this year.
About Zeto, Inc.
Zeto, Inc., is an award-winning, privately held medical technology company located in Santa Clara, CA, focused on transforming the way electroencephalography is done in clinical and research settings.
The company plans to leverage its platform technology to improve access and quality to medical EEG testing and to enable and improve adjacent biomedical research and clinical trials. Zeto’s EEG systems, which received FDA clearances in 2018 and 2024, are currently commercially available in the United States.
To learn more about Zeto’s products, please visit https://zeto-inc.com/ or email us at research@zetoinc.com.
Source: Newswise